Navigation Links
International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
Date:9/27/2007

SINGAPORE, Sept. 27 /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first natural compound to be studied in a large clinical trial focused on stroke recovery starting in the acute stage.

The CHIMES study is a multi-center double-blind placebo-controlled randomized trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment starting within 48 hours of a stroke. Already studied in a rehabilitation setting with initiation of treatment within 14 days of stroke incidence, NeuroAid(TM) will now be evaluated when administered in the acute stage, with periodic assessments for three months. The study will begin enrollment of 1,100 patients in early October 2007 at several hospitals in Singapore, followed by hospitals in the Philippines and in Thailand.

The study will be conducted by CHIMES Society, an international partnership of Key Opinion Leaders in stroke whose objective is to establish new stroke treatments.

Professor Marie-Germaine Bousser, Head of the Neurology Department at Lariboisiere Hospital in Paris, France and member of the Council of the American Stroke Association, commented, ''Recent drug trials in the acute treatment of stroke have unfortunately all been negative. It is thus very exciting to take a completely new approach and to scientifically test in different populations a compound that has long been used in Traditional Chinese Medicine.''

David Picard, CEO of Moleac, the Singapore/Biopolis-based global biopharmaceutical company that develops and markets NeuroAid(TM) outside of China, said: ''We are delighted at the interest NeuroAid(TM) has generated in the medical community worldwide. Over 200,000 patients in China alone are using NeuroAid(TM) every year, and patient feedback from other countries is very positive. Our next milestone is to generate clinical data in the acute phase, with studies that meet the standards of European and U.S
'/>"/>

SOURCE Moleac
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Calif. , June 14 The ... directly to cancer sites with minimal exposure to ... multiple publications, according to Xoft, Inc., developer of ... provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides ...
... of the Pros & Cons of Robotic Surgery , ... PHILADELPHIA , June 11 Robotic surgery -- is it ... campaigns and targeted marketing to physicians? , , ... robots help surgeons perform surgery with greater access, visibility and precision all which reduce ...
Cached Medicine Technology:Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers 2Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers 3Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers 4Robotic Surgery: Medicine or Marketing? 2Robotic Surgery: Medicine or Marketing? 3Robotic Surgery: Medicine or Marketing? 4Robotic Surgery: Medicine or Marketing? 5
(Date:7/30/2015)... ... July 30, 2015 , ... In an effort to provide the twenty ... making a change in his practice. , The decision will also allow him to ... Aggarwal will be transferring his in-patient admissions to the hospitalists at East Liverpool City ...
(Date:7/30/2015)... York, NY (PRWEB) , ... July 30, 2015 ... ... Setria®Glutathione and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, ... Recovery Chewable as a simple way to get the natural ingredients that may ...
(Date:7/30/2015)... ... July 30, 2015 , ... Mullin/Ashley Associates, Inc. ... three awards in the Service Industry Advertising Awards 12th annual national competition. ... Development Corporation and University of Maryland Shore Regional Health. , A Gold Award ...
(Date:7/30/2015)... ... July 30, 2015 , ... Well-known ... of the largest, family-owned low cost service and repair companies. For 35 years, ... well as growing their company to meet the demands of the changing technological ...
(Date:7/30/2015)... ... , ... 24/7 Care At Home, a high-quality provider of comprehensive home health ... Centers for Medicare and Medicaid (CMS) have awarded its agency the highest star rating ... Home’s agency is one of three top Orange County agencies to earn the 5-Star ...
Breaking Medicine News(10 mins):Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2
... to be a killer in Assam with 275 deaths reported ... years, parliament was told Friday.// ,Minister of State ... written reply in the Rajya Sabha that Assam is endemic ... six years starting 2001 with 47,29,65 cases reported. ...
... Scientists at the Stanford University have discovered that skin ... , longitude and altitude to reach their destined place ... this plays an important role in directing the embryonic ... the body that we didn't understand before,’ said John ...
... production of fat and cholesterol, has been identified by ... This may play a major role in advancing the ... type II diabetes and high blood pressure. ,"We ... a family of molecular switches to turn on cholesterol ...
... may have more functions in reproduction than merely being ... that the semen from fertile men contains a multitude ... Hormone) initiates ovulation. Some other hormones are reported to ... ,The researcher, Rebecca Burch, thinks human males have evolved ...
... in the diet of some Irish women has put them ... even attention problems//, according to the preliminary results of a ... ,A team of researchers at University College Dublin (UCD, ... consuming enough iodine. This could adversely affect the development of ...
... implication when tiny particles in the air is inhaled, ... rats inhale// , nano-sized particles quickly traverse the pathway ... This study is published in the August issue of ... gene expression, which the researchers found, that could signal ...
Cached Medicine News:Health News:Skin Cells Make Use of Geographic Co-Ordinates to Reach Their Destination 2Health News:Skin Cells Make Use of Geographic Co-Ordinates to Reach Their Destination 3Health News:A Major Break Through in Treatment for Metabolic Syndrome 2Health News:A Major Break Through in Treatment for Metabolic Syndrome 3Health News:A Major Break Through in Treatment for Metabolic Syndrome 4Health News:Iodine Deficiency affects IQ of Children 2Health News:Nano-sized inhaled particles traverse quickly from nose to brain 2
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
Inquire...
... Rotor has a standard 1.5ml rotor and 6 ... Easy operation (no switches to mess with). Simply ... the plastic tab to open. Starts and stops ... 2000 x g. Only five inches in diameter. ...
Inquire...
Medicine Products: